More than three-quarters agree Intellectual Property standards should be
at least the same as our major trading partners
OTTAWA, Sept. 16, 2012 /CNW/ - More than three-quarters of Canadians
agree this country needs better or the same protection of intellectual
property (IP) as our major trading partners, say figures from a Nanos
Research survey conducted last week.
When asked whether Canada should have more, the same or less protection
for IP as our major trading partners, more than 76% agreed Canada's IP
regime should be at least the same or stronger.
"There is a significant majority of Canadians who expect a level of
intellectual property protection that is equivalent or even greater
than that of our key western trading partners like the United States or
Europe," says Nik Nanos, President and CEO of Nanos Research. "It is
also important to note that a very small minority, only 12.4%, of
Canadians think we need less intellectual property protection. It is a
clear signal that Canadians assign a significant level of value to
Improving Canada's pharmaceutical IP standards remains one outstanding
issue to be concluded in the negotiations towards a landmark
Comprehensive Economic and Trade Agreement (CETA) between Canada and
the European Union.
This opportunity for Canada would strengthen protections for
intellectual property by harmonizing data protection to EU standards,
allowing patent restoration for time lost while new medicines are in
the government approval process and permitting an effective right of
appeal in patent invalidity cases for research-based drug companies.
"The discovery and development of innovative new medicines and vaccines
is fundamental to improving the health of Canadians, as well as
ensuring Canada's health-care system is sustainable well into the
future," says Russell Williams, President of Canada's Research-Based
Pharmaceutical Companies (Rx&D). "CETA offers us an opportunity to
strengthen protections for health innovation so that we can attract
international investment and encourage research and development right
here at home, in Canada. It is clear Canadians understand the value of
strong IP in improving health care and achieving economic growth."
"Most Canadians have experienced the transformative power of new
medicines either first-hand or through someone they care about. They
understand the value and want to ensure that health discovery and
innovation continues," says Williams. "If we want to be part of it, we
need the tools to win more life science investments for Canada.
Stronger IP is an important tool."
The Nanos Research national representative online survey of 1,000
Canadians aged 18 and over was conducted between September 10th and
11th, 2012 and is an accurate representation of opinion at the time of
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents the men and women working for more than 50 member companies
and invests more than $1 billion in research and development each year
to fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
For all questions related to the research please contact:
Nik Nanos, CMRP President & CEO Nanos Research
Telephone: 613-234-4666 ext. 237
SOURCE: CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)
For further information:
Vice President, Public Affairs & Partnerships
Telephone: 613-236-0455 ext. 627